Travere Therapeutics
TVTX
169 hedge funds and large institutions have $1.7B invested in Travere Therapeutics in 2022 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 62 increasing their positions, 61 reducing their positions, and 21 closing their positions.
82% more call options, than puts
Call options by funds: $4.43M | Put options by funds: $2.43M
2.39% more ownership
Funds ownership: 107.65% → 110.04% (+2.4%)
5% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 21
2% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 61
0% more funds holding
Funds holding: 169 → 169 (0)
0% more funds holding in top 10
Funds holding in top 10: 8 → 8 (0)
16% less capital invested
Capital invested by funds: $2.03B → $1.7B (-$327M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$23.4M |
| 2 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$18.3M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$18.2M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$16.8M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$16.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$18.4M |
| 2 |
Public Sector Pension Investment Board (PSP Investments)
Montreal,
Quebec, Canada
|
-$11.1M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$10.2M |
| 4 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
-$8.64M |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$8.3M |
TVTX Hedge Fund Activity: Q1 2022 in Review
169 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q1 2022, worth a combined $1.7B — down 16% from $2.03B a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new TVTX positions and 21 closed out — a net gain of 1 holder — while 62 added to existing stakes and 61 trimmed.
The largest buyer was Armistice Capital, adding an estimated $23.4M. The largest seller was RA Capital Management, cutting an estimated $18.4M.
- 169 institutional investors held Travere Therapeutics (TVTX) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $1.7B of Travere Therapeutics stock for Q1 2022, down 16% quarter-over-quarter.
- 22 funds opened new Travere Therapeutics positions in Q1 2022 and 21 closed out, a net change of +1 holder.
- The largest Travere Therapeutics buyer in Q1 2022 was Armistice Capital, an estimated $23.4M added.
- The largest Travere Therapeutics seller in Q1 2022 was RA Capital Management, an estimated $18.4M sold.
Based on aggregated 13F filings for Q1 2022.